Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Transcription

1 Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April

2 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics company based in Oxford Focused on delivering improved solutions for accurate disease analysis and early disease detection Self-financing, with headline revenues of 10m Operating in 30 countries worldwide, with ambitious US plans Poised for period of significant value creation, based on strong market position and rapid advances in the molecular medicine sector Experienced management, originating from premier companies including Amersham (GE Healthcare), GSK, Affymetrix 2

3 The molecular medicine landscape A rapidly evolving revolution in healthcare 3

4 The molecular medicine landscape OGT s competitive advantage Next Generation Sequencing Biomarkers Accurate, meaningful results Array technologies Sample preparation Companion diagnostics Consumer genomics Genomic medicine DNA testing 4

5 Premier league customers 5

6 Balanced business model Delivering revenue growth & significant investment upside Accurate disease analysis Early disease detection Genomic products and services Meaningful results Internal biomarker programmes 6

7 Balanced business model Delivering revenue growth & significant investment upside Accurate disease analysis Early disease detection Constitutional arrays Prostate cancer Molecular testing arrays Cancer arrays Genomic products and services Cancer panels Sequencing services Array services Meaningful results Colorectal cancer Internal biomarker programmes Lupus Non-invasive prenatal screening 7

8 Genomic products and services Accurate disease analysis CytoSure Cytogenetic Products for the research into genetic disease Technology: Microarrays and analysis software Applications: Constitutional disorders (e.g. learning disorders) Haematological cancer Genefficiency Genomic Services for research into genetic disease Technologies: DNA microarrays Next generation sequencing Applications: All genetic diseases 8

9 $Millions Cytogenetics market Forecast for rapid growth Market growth driven by: Increasing adoption of molecular techniques (e.g. microarrays) Oncology applications Growing public awareness and demand for personalised medicine * Global Industry Analysts, Inc

10 CytoSure What is CytoSure? A microarray (glass slide) with thousands of expertly designed DNA fragments (probes) printed on the surface Coupled with sophisticated labelling and interpretative software to aid analysis What does it do? Allows comparison of normal and disease samples to accurately detect learning disorders and haematological cancers Why is it different? Enables much easier and more accurate interpretation of data 10

11 CytoSure Extensive product range Constitutional genetics research Developmental delay (e.g., autism) Cancer cytogenetics research Leukaemia, myeloma Molecular genetics research Heart disease, diabetes, Duchenne muscular dystrophy Arrays CytoSure ISCA/ISCA SNP CytoSure Syndrome Plus CytoSure Aneuploidy CytoSure Haematological Cancer + SNP CytoSure Molecular Testing CytoSure DMD Reagents CytoSure Genomic DNA Labelling Kits Automation Full automation options Software CytoSure Interpret Software Meaningful results 11

12 CytoSure The complete solution for clinical genetics research 12

13 CytoSure Strong foundations for significant growth CytoSure sold to 30 countries High-profile customer base Comprehensive product range Class-leading analysis software New US office CytoSure development plan Expand product range: Pre-natal, pre-implantation genetic screening, cancer, companion products Acquisition of new technology to develop additional tests 13

14 Genomic services market Rapidly evolving and growing sector Market size: Genomics market estimated to be $6.5b* Next Generation Sequencing (NGS) is estimated to be $1.1b with double digit growth* Market growth driven by: Rigorous quality control required by large genomic studies and clinical research samples Rapid and straightforward interpretation of large volumes of data into meaningful results Quick turnaround times Genomics market estimated to be $6.5b* (NGS) is estimated to be $1.1b with double digit growth* $1.1b* * DeciBio,

15 Sequencing to understand disease Hitting the headlines 15

16 Genefficiency What is Genefficiency? World-leading accurate, high-throughput genomic services What does it do? Utilises the latest genomic technologies (e.g. microarrays and next generation sequencing) and analysis techniques to identify the genetic causes of disease Why is it different? High throughput over 2,000 samples/week Higher quality unique quality management system & accreditations Expert data analysis rapid identification of causative mutations 16

17 Genefficiency Ideally positioned to capture significant share of genomic services market Global sales High-profile customer base Awarded 3 high profile grants: June 2011: 1.2m TSB tumour profiling service March 2012: 1.5m EU infectious disease March 2012: 920k EU predisposition to infection Genefficiency development plans: Expand available platforms and applications Drive the implementation of clinical sequencing 17

18 Internal biomarker programmes Early disease detection Biomarker discovery pipeline Patent protected portfolio Proprietary technology Leverage links with research institutions Experienced team Development focus Areas of unmet medical need Large potential markets Primarily cancer and autoimmune disease Balanced development strategy 18

19 OGT s biomarker discovery pipeline Feasibility study Sample recruitment Biomarker discovery Biomarker validation Clinical validation Colorectal cancer Second most frequent cancer in the developed world Current tests low specificity and poor patient compliance OGT biomarker panel delivers sensitivity and specificity >90% Promising data in detection of adenomas and early-stage cancer Prostate cancer Most common male cancer ~260,000 deaths per annum Current test very low specificity (~30%) resulting in unnecessary treatment 30 million tests annually in US alone (market size approx. $3 billion) OGT panel sensitivity and specificity >80%; ability to measure aggressiveness Lupus Autoimmune disease affecting 1 in 500 African Americans, 1 in 2,500 Europeans Current test low specificity 57% OGT biomarker panel delivers specificity of 89% 19

20 OGT s biomarker commercialisation strategy Colorectal cancer Requires extensive sales network More rapid sales achieved via partnership Out-license Prostate cancer Significant CLIA laboratory service opportunity Aggressiveness rather than screening application Specialist customer base Develop in-house Lupus Specialist autoimmune diagnostic market Smaller market size Out-license 20

21 million OGT Group: financial position Commercial Revenues* F2013 CytoSure Services Private, self-financing company Sustained revenue growth CAGR of >85% pa Growth Feb YTD +45% * For financial years ending 30 September, excludes patent revenues and royalties. 21

22 OGT growth strategy Strong Strong foundation Sustained organic growth Acceleration foundation Addressing high growth markets New product launches to drive revenue and margin growth Expansion into new territories and adjacent markets Higher value business models Selective acquisitions and investments Focus on cytogenetics research Cancer arrays NGS disease panels US salesforce Asia expansion Pre-natal testing Pre-implantation genetic screening Cancer biomarkers Non-invasive prenatal screening (NIPS) Cytogenetics companies Biomarker validation 22

23 The molecular medicine landscape Growing market capitalisations and high multiple transactions Peer group companies Multi million/billion transactions in the molecular medicine space Sept 2012 Acquired by Illumina for $100m Market Cap: $588.6m NASDAQ:SQNM April 2012 Rejected bid from Roche for $6.7.bn May 2012 Acquired by Agilent for $2.2bn Feb 2012 Predicted value at IPO bn Market Cap: $620.41M NASDAQ April 2012 Acquired by Quest Diagnostics for $740m Dec 2011 Acquired by LabCorp for $85m 23

24 Summary World-class potential, with strong reputation and increasing share in large and growing molecular medicine space Global sales, with ambitious expansion plans Premier league customer base Experienced management team with proven ability Well financed with risk diversified business model 24

25 Innovative genetics research and biomarker solutions to advance molecular medicine CytoSure and Genefficiency NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures 25